CO6491061A2 - Formulacion de omeprazol farmaceutica estable para administracion oral - Google Patents

Formulacion de omeprazol farmaceutica estable para administracion oral

Info

Publication number
CO6491061A2
CO6491061A2 CO12007902A CO12007902A CO6491061A2 CO 6491061 A2 CO6491061 A2 CO 6491061A2 CO 12007902 A CO12007902 A CO 12007902A CO 12007902 A CO12007902 A CO 12007902A CO 6491061 A2 CO6491061 A2 CO 6491061A2
Authority
CO
Colombia
Prior art keywords
formulation
agent
oral administration
pharmaceutical
stable
Prior art date
Application number
CO12007902A
Other languages
English (en)
Inventor
Erik Juvonen
Louis Massimo Micolucci
Original Assignee
Vetegen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43465734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6491061(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vetegen Llc filed Critical Vetegen Llc
Publication of CO6491061A2 publication Critical patent/CO6491061A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación de jarabe farmacéutica agradable y estable para administración oral que comprende omeprazol o una sal de omeprazol, un agente solubilizante, un agente basificante, un agente edulcorante, un agente aromatizante, un antioxidante y un tampón. La formulación comprende además un agente antimicrobiano seleccionado del grupo que consiste en ácido benzoico y benzoato de sodio, un potenciador de la solubilidad que consiste en ciclodextrinas, polisorbato y Kollidon, un modificador de la viscosidad que consiste en una fuente de celulosa y goma xantana. La presente invención también se refiere al método de preparación de una formulación de jarabe farmacéutica.
CO12007902A 2009-07-20 2012-01-19 Formulacion de omeprazol farmaceutica estable para administracion oral CO6491061A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22689009P 2009-07-20 2009-07-20

Publications (1)

Publication Number Publication Date
CO6491061A2 true CO6491061A2 (es) 2012-07-31

Family

ID=43465734

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12007902A CO6491061A2 (es) 2009-07-20 2012-01-19 Formulacion de omeprazol farmaceutica estable para administracion oral

Country Status (11)

Country Link
US (1) US8530500B2 (es)
EP (1) EP2456439A4 (es)
JP (1) JP2012533633A (es)
AU (1) AU2010276404A1 (es)
CA (1) CA2768024A1 (es)
CL (1) CL2012000169A1 (es)
CO (1) CO6491061A2 (es)
EC (1) ECSP12011618A (es)
IN (1) IN2012DN00359A (es)
PE (1) PE20120781A1 (es)
WO (1) WO2011011351A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088109A1 (en) * 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB2561355A (en) * 2017-04-10 2018-10-17 Eaststone Ltd Pharmaceutical composition and a method for manufacturing the same
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
GB2616663A (en) * 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
SK286371B6 (sk) * 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Also Published As

Publication number Publication date
CA2768024A1 (en) 2011-01-27
PE20120781A1 (es) 2012-06-27
US20110015233A1 (en) 2011-01-20
AU2010276404A1 (en) 2012-02-02
ECSP12011618A (es) 2012-04-30
EP2456439A2 (en) 2012-05-30
WO2011011351A3 (en) 2011-05-19
JP2012533633A (ja) 2012-12-27
CL2012000169A1 (es) 2012-08-31
EP2456439A4 (en) 2012-12-26
US8530500B2 (en) 2013-09-10
IN2012DN00359A (es) 2015-05-22
WO2011011351A2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
CY1124690T1 (el) Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
CO6210803A2 (es) Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
IN2012DN00407A (es)
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
ES2605495T3 (es) Solución de atomoxetina
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
US11304910B2 (en) Soft gelatin capsules with pH-independent release
JP2015531377A5 (es)
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
WO2011056532A3 (en) Bazedoxifene formulations with antioxidants
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
WO2020053662A3 (en) Non-aqueous solutions for oral dosage
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
JP7359909B2 (ja) 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。
RU2007136310A (ru) Способ получения наноразмерной системы доставки лекарственных средств на основе диоксида кремния
WO2009048940A3 (en) Diacerein pharmaceutical formulations

Legal Events

Date Code Title Description
FC Application refused